10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Since the novel coronavirus pandemic outbreak, and with no available vaccines or treatment, many dozens of existing medicines have been trialled in the setting, so far with few successes. 29 July 2020
Shares of Belgium’s largest drugmaker UCB were barely moved in early trading, despite the announcement of a potentially massive licensing deal for its Alzheimer’s candidate. 29 July 2020
The Alliance for Regenerative Medicine (ARM) has called for pan-European action to fast-track the use of real world evidence (RWE) for advanced therapy medicinal products (ATMPs) to help ensure patient access to transformative therapies. 29 July 2020
Infectious diseases specialist Nabriva Therapeutics has won European approval for Xenleta (lefamulin), for the treatment of community-acquired pneumonia (CAP) in adults. 29 July 2020
US biotech giant Amgen late Tuesday announced financial results for the second quarter of 2020, which, although better than analysts’ expectations, pushed the firm’s shares down 1.5% to $251.50 in after-hours trading. 29 July 2020
Cancer Research UK, the University of Southampton and London-based biotech Touchlight Genetics, today (July 29) announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC). 29 July 2020
AbbVie’s aspiring blockbuster Rinvoq (upadacitinib) is on course for a second indication following the presentation of pivotal Phase III results in atopic dermatitis (AD). 28 July 2020
Oral peptide specialist Chiasma has announced positive data from the Phase III CHIASMA OPTIMAL open-label extension (OLE) study of Mycapssa (octreotide). 28 July 2020
The US Department of Health and Human Services has reserved the available advanced manufacturing capability and capacities of the Center for Innovation in Advanced Development and Manufacturing (CIADM) at the Texas A&M University System for use in manufacturing COVID-19 vaccines. 28 July 2020
BioNTech and Pfizer have revealed the start of a global (except for China) Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program, against SARS-CoV-2. 28 July 2020
Swiss giant Roche has exercised an option to increase the scope and value of a research project with UK-based immunodiagnostics firm Oncimmune Holdings. 27 July 2020
Japanese drugmaker Daiichi Sankyo (TYO: 4568) saw its shares rise more than 4% to 8.712 yen, after it revealed another multi-billion licensing deal, potentially worth $6 billion. 27 July 2020
The US Food and Drug Administration has granted accelerated approval to Tecartus (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 27 July 2020
mRNA therapeutics and vaccines specialist Moderna Therapeutics has secured an additional $472 million from the US authorities for late-stage development of mRNA-1273. 27 July 2020
North Carolina, USA-based oncology specialist G1 Therapeutics has signed a license agreement for lerociclib to EQRx, a biopharmaceutical company focused on making innovative medicines at dramatically lower prices for the benefit of people and society. 24 July 2020
Chinese publication Science and Technology Daily has analyzed the progress of the AstraZeneca and University of Oxford coronavirus vaccine alongside a competitor from China. 24 July 2020
UCB today announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational interleukin (IL)-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Novartis’ (NOVN: VX) Cosentyx (secukinumab) in the treatment of adult patients with moderate-to-severe plaque psoriasis. 24 July 2020
After a run of positive announcements on the clinical side, mRNA therapeutics and vaccines developer Moderna Therapeutics has been struck with a patent blow, knocking 10% off its share price. 24 July 2020
Shares in CymaBay Therapeutics have been lifted by a quarter after the liver disease specialist announced multiple clinical holds for seladelpar had been lifted. 24 July 2020